The First Bottles of Medical Cannabis Oil Delivered to Patients in Jujuy, Argentina

The Government of Jujuy delivered the first 50 bottles of pharmaceutical-grade medical cannabis oil to patients included in the special therapeutic program. Moreover, the government confirmed that in November the medical cannabis oil will be available in 160 pharmacies in Jujuy for sale under medical prescription.

“We are proud to be marking this milestone, the most important of the project,” assured the radical governor Gerardo Morales.

The governor highlighted that this is the first cannabis-derived product entirely manufactured in the country from the active pharmaceutical ingredient, elaborated by the company Cannava S.E. at Finca El Pongo, in Perico.

The Hemp.im application organizes what’s happening in the cannabis world to help you learn more about the stories that matter to you. Stay informed with the latest hemp news and get the important information in one application.

The medical cannabbil oil produced by Cannava will be available in 160 pharmacies

During a ceremony at the Arturo Zabala hospital in that town, Morales also highlighted that “it is a project that started a little more than three years ago” and that “its heart has to do with health but also with scientific and technological development because there is no other province in the country that has the level of scientific and technological progress and development that Jujuy has.”

The cannabis oil manufactured by Cannava – “CBD 10”- was delivered “free of charge and for life” to beneficiaries in the province, children and adults, who were accompanied by their relatives.

The product will be available from November in 160 pharmacies in the province, and it will be available through a prescription.

“We know that there is the political decision of the national government to promote this project and this challenge; we have fulfilled the different stages with the respective authorizations and regulations and there is no leap into the void or improvisation here, but a scientific and technological work that is at the best levels of drug production in the world,” he said.

Along these lines, Morales specified that they are complying “with the GMP standard, which are the good manufacturing practices standards required by the European Union so that we can enter Europe when we have greater production”.

The intention, he said, is not only to supply pharmacies and hospitals in Jujuy and the country. “We are going to enter Brazil, Europe and the countries that demand a high-quality product”, he highlighted, and estimated that “in March or April it could be sold all over the country and go out to the world.”

__

(Featured image by CBD-Infos-com via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in ambito, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.